# Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

> **NCT06981325** · PHASE2 · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 34 (estimated)

## Conditions studied

- Basal Cell Carcinoma (BCC)
- First Line Treatment

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT06981325
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2028-10
- **Final completion:** 2029-07
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981325, "Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06981325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*